statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the first patient was dosed in the Phase 2 dose expansion part of the...

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) will hold its Annual General Meeting of Shareholders (AGM) at 10:30 a.m. CEST on May 23, 2024 in its...

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that first preclinical data for its asset IPH45, a novel and differentiated...

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that members of its executive team are scheduled to participate in the upcoming investor...

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the filing of its 2023 Universal Registration Document (Document denregistrement...

Innate Pharma Files Its 2023 Universal Registration Document (Document denregistrement Universel) and 2023 Annual Report on Form 20-F

Innate Pharma S.A. (IPHYF) has disclosed a new risk, in the Employment / Personnel category. Innate Pharma S.A. faces significant business risk as...

Innate Pharma's Growth at Risk: The Challenge of Relying on External Partners and a Lean Team

HC Wainwright reiterated their buy rating on shares of Innate Pharma (NASDAQ:IPHA  Free Report) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $11.50 price...

Innate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC Wainwright

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the year ending December 31, 2023. The consolidated...

Innate Pharma Reports Full Year 2023 Financial Results and Business Update

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET...

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Watchers	1,442
52-Wk Low	$1.81
52-Wk High	$3.57

Volume	2,580.00
52-Wk High	$3.57
52-Wk Low	$1.81

IPHA Innate Pharma

About

Feed

News

Sentiment

Earnings

Fundamentals